Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155269172> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2155269172 endingPage "842" @default.
- W2155269172 startingPage "S" @default.
- W2155269172 abstract "often had history of alcohol consumption; and had more severity of liver disease determined by higher MELD score and lower serum albumin level compared with patients receiving interferon therapy. Of 159 treated patients, 116 (73%) were classified as achieving a SVR, 22 as non-responders, and 21 as transient-responders. The older age, history of alcohol consumption, and higher MELD score were significantly associated with the development of liver failure defined as new onset of ascites, variceal bleeding, jaundice, or hepatic encephalopathy. After adjusting for age, alcohol consumption, and MELD score, SVR (HR 0.21; 95% CI 0.09-0.43), and non-SVR (HR 0.31; 95% CI 0.13-0.67) was associated with a reduction in the risk of liver failure compared with no treatment. During a median followup of 43.8 months (range: 12-137) the incidence rates per 100 person-years of HCC development were 3.17 among SVR, 10.8 among non-SVR, and 8.17 among untreated group. Comparison with no treatment, a reduction in the risk of HCC development was associated with SVR (HR 0.37; 95% CI 0.18-0.74) but was not associated with non-SVR (HR 1.02; 95% CI 0.99-1.06) after adjusting for age. Of 58 patients with HCC, tumor characteristics on contrast-enhanced images and stage of cancer were not different between 3 groups. Among cancers, observed survival in SVR group (p=.02) and non-SVR group (p<.001) was longer than that of untreated group. Conclusion: Antiviral treatment with interferon for compensated HCV-related cirrhosis reduces the risk for liver failure and HCC, especially among sustained responders. The survival advantage of antiviral therapy among cancers might be due to a reduction in the risk of liver failure." @default.
- W2155269172 created "2016-06-24" @default.
- W2155269172 creator A5026205612 @default.
- W2155269172 creator A5026436974 @default.
- W2155269172 creator A5031244489 @default.
- W2155269172 creator A5042913578 @default.
- W2155269172 creator A5045505103 @default.
- W2155269172 creator A5079571449 @default.
- W2155269172 creator A5087992950 @default.
- W2155269172 creator A5090834989 @default.
- W2155269172 date "2010-05-01" @default.
- W2155269172 modified "2023-10-16" @default.
- W2155269172 title "T1981 The Association of Leptin Reduction With Efficacy of Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C" @default.
- W2155269172 cites W2092876900 @default.
- W2155269172 doi "https://doi.org/10.1016/s0016-5085(10)63877-2" @default.
- W2155269172 hasPublicationYear "2010" @default.
- W2155269172 type Work @default.
- W2155269172 sameAs 2155269172 @default.
- W2155269172 citedByCount "0" @default.
- W2155269172 crossrefType "journal-article" @default.
- W2155269172 hasAuthorship W2155269172A5026205612 @default.
- W2155269172 hasAuthorship W2155269172A5026436974 @default.
- W2155269172 hasAuthorship W2155269172A5031244489 @default.
- W2155269172 hasAuthorship W2155269172A5042913578 @default.
- W2155269172 hasAuthorship W2155269172A5045505103 @default.
- W2155269172 hasAuthorship W2155269172A5079571449 @default.
- W2155269172 hasAuthorship W2155269172A5087992950 @default.
- W2155269172 hasAuthorship W2155269172A5090834989 @default.
- W2155269172 hasBestOaLocation W21552691721 @default.
- W2155269172 hasConcept C126322002 @default.
- W2155269172 hasConcept C159047783 @default.
- W2155269172 hasConcept C203014093 @default.
- W2155269172 hasConcept C2522874641 @default.
- W2155269172 hasConcept C2776178377 @default.
- W2155269172 hasConcept C2776455275 @default.
- W2155269172 hasConcept C2776461080 @default.
- W2155269172 hasConcept C2780040827 @default.
- W2155269172 hasConcept C3020491458 @default.
- W2155269172 hasConcept C71924100 @default.
- W2155269172 hasConcept C90924648 @default.
- W2155269172 hasConceptScore W2155269172C126322002 @default.
- W2155269172 hasConceptScore W2155269172C159047783 @default.
- W2155269172 hasConceptScore W2155269172C203014093 @default.
- W2155269172 hasConceptScore W2155269172C2522874641 @default.
- W2155269172 hasConceptScore W2155269172C2776178377 @default.
- W2155269172 hasConceptScore W2155269172C2776455275 @default.
- W2155269172 hasConceptScore W2155269172C2776461080 @default.
- W2155269172 hasConceptScore W2155269172C2780040827 @default.
- W2155269172 hasConceptScore W2155269172C3020491458 @default.
- W2155269172 hasConceptScore W2155269172C71924100 @default.
- W2155269172 hasConceptScore W2155269172C90924648 @default.
- W2155269172 hasIssue "5" @default.
- W2155269172 hasLocation W21552691721 @default.
- W2155269172 hasOpenAccess W2155269172 @default.
- W2155269172 hasPrimaryLocation W21552691721 @default.
- W2155269172 hasRelatedWork W1972048077 @default.
- W2155269172 hasRelatedWork W1989253246 @default.
- W2155269172 hasRelatedWork W2040072090 @default.
- W2155269172 hasRelatedWork W2170099051 @default.
- W2155269172 hasRelatedWork W2220604806 @default.
- W2155269172 hasRelatedWork W2278023447 @default.
- W2155269172 hasRelatedWork W2410696600 @default.
- W2155269172 hasRelatedWork W2411773677 @default.
- W2155269172 hasRelatedWork W246869748 @default.
- W2155269172 hasRelatedWork W2921216494 @default.
- W2155269172 hasVolume "138" @default.
- W2155269172 isParatext "false" @default.
- W2155269172 isRetracted "false" @default.
- W2155269172 magId "2155269172" @default.
- W2155269172 workType "article" @default.